Treatment Options for Metastatic Castrate-Resistant Prostate Cancer (mCRPC) After Progression on 3rd Line Enzalutamide

Introduction to mCRPC Treatment Guidelines

The NCCN guidelines and ASCO guidelines for mCRPC focus exclusively on systemic therapies for patients with metastatic disease, including androgen receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, and immunotherapy 1, 2, 3.

The American College of Clinical Oncology recommends docetaxel 75 mg/m² IV every 3 weeks plus prednisone 10 mg daily as the standard chemotherapy regimen for mCRPC patients who have progressed on androgen receptor pathway inhibitors, with a demonstrated overall survival benefit 3, 5, 6.
The European Association of Urology suggests cabazitaxel 25 mg/m² IV every 3 weeks plus prednisone for patients who progress after docetaxel chemotherapy, providing moderate survival benefit but carrying moderate-to-high toxicity risk 3.
The American Society of Clinical Oncology recommends radium-223 dichloride 55 kBq/kg IV every 4 weeks for 6 doses for patients with symptomatic bone metastases and no visceral metastases, improving overall survival and delaying skeletal-related events with low toxicity 3.

Palliative radiation to symptomatic bone metastases (typically 8 Gy in 1 fraction or 20 Gy in 5 fractions) is appropriate for pain control or prevention of pathologic fracture, as recommended by the Journal of Clinical Oncology 3, 6.
The National Comprehensive Cancer Network guidelines advise continuing androgen deprivation therapy indefinitely, as all patients with mCRPC should maintain castrate testosterone levels regardless of additional therapies 3.
The American College of Clinical Oncology suggests initiating palliative care early, as all patients with mCRPC should be offered palliative care services concurrently with disease-directed therapy 3.